Orion Portfolio Solutions LLC Sells 10,298 Shares of Haleon plc (NYSE:HLN)

Orion Portfolio Solutions LLC cut its stake in Haleon plc (NYSE:HLN) by 2.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 379,174 shares of the company’s stock after selling 10,298 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Haleon were worth $3,617,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of HLN. Sierra Ocean LLC acquired a new position in Haleon in the 4th quarter valued at about $26,000. Versant Capital Management Inc boosted its holdings in shares of Haleon by 2,029.1% during the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after acquiring an additional 3,348 shares during the period. Geneos Wealth Management Inc. acquired a new position in shares of Haleon in the fourth quarter valued at approximately $35,000. Toronto Dominion Bank increased its stake in shares of Haleon by 3,470.0% during the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after purchasing an additional 3,470 shares during the period. Finally, Spire Wealth Management acquired a new stake in Haleon during the 4th quarter worth approximately $39,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Stock Up 1.1 %

HLN stock opened at $10.24 on Monday. Haleon plc has a 52 week low of $7.99 and a 52 week high of $10.80. The business has a 50-day simple moving average of $9.94 and a 200 day simple moving average of $9.87. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The company has a market cap of $46.33 billion, a PE ratio of 30.10, a price-to-earnings-growth ratio of 2.82 and a beta of 0.25.

Haleon (NYSE:HLN) last issued its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The company had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. Sell-side analysts anticipate that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The firm also recently announced a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be paid a dividend of $0.1166 per share. The ex-dividend date is Friday, April 25th. This is a boost from Haleon’s previous — dividend of $0.05. This represents a yield of 1.6%. Haleon’s dividend payout ratio is presently 58.97%.

Wall Street Analysts Forecast Growth

HLN has been the topic of a number of research reports. Hsbc Global Res lowered Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Sanford C. Bernstein downgraded shares of Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Morgan Stanley downgraded shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Finally, HSBC reaffirmed a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Six analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.